Brought to you by 
Spectrum gets certain rights to TopoTarget's belinostat
14 Dec 2015
Executive Summary
Oncology companies Spectrum Pharmaceuticals and TopoTarget AS have signed an agreement for the development and commercialization of the latter's HDAC inhibitor belinostat, which is in approximately 20 clinical trials for blood cancers and solid tumors.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Spectrum gets certain rights to TopoTarget's belinostat
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice